Inclusive Trial Access Inato’s mission to broaden access to clinical trials suggests a partnership opportunity with sponsors aiming to diversify trial populations and decentralize sites. Sales discussions can emphasize how their platform can unlock patient access from community-based sites, accelerating enrollment and improving trial representativeness.

Expanded Site Network With a target to activate 95% of underutilized sites and improve site enrollment performance, there is a clear upsell path to sponsors seeking more diverse site engagement and faster enrollment timelines across a broader geographic footprint.

High-Performance Platform The platform offers exclusive site profiles, trial application and verification, and ongoing sponsor support, which can be positioned as reducing sponsor risk and time-to-enrollment while ensuring compliance and enrollment targets through enhanced site vetting.

Strategic Partnerships Recent funding activity and ecosystem links to Web3 and technology partners indicate potential for collaboration on analytics, data governance, and extended support services, presenting cross-sell opportunities to technology-forward pharma and CROs.

Sustainability and Impact By enabling more inclusive trials across diverse communities, Inato can be positioned to sponsors with ESG and patient access commitments, offering a narrative for value-based partnerships and potential grant-aligned funding discussions.